Basically we licenced our patents to Tigenix / Takeda for the Cx601 / Darvadstrocel / Alofisel MSC cell line.
The trials were done in Spain lead by Prof Damian Garcia-Olmo at the Health Research Institute Foundation Jimenez Diaz (IIS-FJD) Madrid, Spain and approved by the EMA.
https://www.clinicaltrialsarena.com/projects/alofisel-darvadstrocel-treatment-complex-perianal-fistulas-crohns-disease/
No idea what the FDA is going to do.
Basically we licenced our patents to Tigenix / Takeda for the...
-
- There are more pages in this discussion • 11,923 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |